ERBB2 and breast carcinoma: Although 46 patients had received NAC for HER2-positive breast cancer, nine patients were participating in the PASSION trial, and three patients had received fewer than three courses of pertuzumab-based combination therapy; thus, these 12 patients were excluded from the study (Figure 1).